JULES A. MUSING - Corporate Board Profile

TherapeuticsMD, Inc.

Filing Date	Source Excerpt
2013-07-12	Jules A. Musing has served as a director of our company since May 2013... Not included in the Director Compensation table for 2012.
2014-04-17	Jules A. Musing compensation for the year ended December 31, 2013 was $60,287.
2015-04-30	Jules A. Musing has served as a director of our company since May 2013. ... The Compensation Committee currently consists of Messrs. Collins, Carroll, and Thompson, with Mr. Collins serving as Chairman. Mr. Musing served on the Compensation Committee until June 23, 2014. ... We compensate our directors with a combination of cash and equity. Each director receives an annual base cash retainer of $50,000 for such service and an annual grant of stock options to purchase 45,000 shares of our common stock. ... During 2014, Jules Musing received an additional stock option grant to purchase 250,000 shares of our common stock that will vest over a four year period for consulting services. ... The following table and accompanying footnotes detail compensation paid to our directors for services rendered for the year ended December 31, 2014. ... Jules A. Musing $50,000 $953,844 $0 $1,003,844.
2016-04-28	Jules A. Musing has served as a director of our company since May 2013. ... We believe Mr. Musing's more than 36-years' experience in the pharmaceutical and biotechnology industry, including the establishment of numerous strategic and global partnerships and various new product collaborations provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors.
2017-04-25	Jules A. Musing has served as a director of our company since May 2013. ... Mr. Musing received his Master’s Degree in Biological Sciences from the University of Brussels (Belgium) and his Graduate Degree in Economics and Financial Sciences from the University of Antwerp (Belgium). ... The following table and accompanying footnotes detail compensation paid to our directors for services rendered for the year ended December 31, 2016. Jules A. Musing $64,500 fees earned or paid in cash, $89,503 option awards, total $154,003.
2018-04-27	Jules A. Musing has served as a director of our company since May 2013. ... Jules A. Musing Fees Earned or Paid in Cash: $64,250, Option Awards: $165,115, Total: $229,365.
2019-04-30	Jules A. Musing has served as a director of our company since May 2013. ... Member of Nominating and Corporate Governance Committee. ... Director Compensation table shows $65,000 fees earned in cash and $180,039 option awards, total $245,039.
2020-05-04	Jules A. Musing has served as a director of our company since May 2013. ... Mr. Musing received his Master’s Degree in Biological Sciences from the University of Brussels (Belgium) and his Graduate Degree in Economics and Financial Sciences from the University of Antwerp (Belgium).
2021-04-14	Jules A. Musing has served as a director of our company since May 2013. In the course of Mr. Musing’s 44-year career in the pharmaceutical and biotechnology industry, specifically at Johnson & Johnson and its affiliates, he has been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances. This included the establishment of new scientific, technology and product collaborations in various therapeutic areas, the negotiation of licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide, and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets. Prior to moving into those roles, Mr. Musing was Vice President Marketing International for the Janssen Pharmaceutical Group of Companies Worldwide from March 1982 to December 1984; a member of the Board of Directors of Johnson & Johnson Pharmaceutical Companies in the UK, Italy and Germany from March 1982 to December 1984; President of Pitman-Moore, Inc., a U.S.-based Johnson & Johnson company from January 1985 to June 1987; Managing Director of Janssen Pharmaceutical in Portugal from July 1987 to March 1990; CEO & President of Ares-Serono, Inc. in the United States and Executive Vice President with responsibilities for North and South America from April 1990 to January 1993; Member of the board of directors of Ortho Biotech, Inc. from January 1993 to October 1999; and Managing Director of Ortho Biotech in France (a Johnson & Johnson affiliate) from October 1999 to January 2003. From January 2003 until his retirement in September 2010, Mr. Musing served as Vice President, Licensing and Acquisitions for the Pharmaceutical Group at Johnson & Johnson, where he was responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology products in all therapeutic areas. He has served as a director of iBio, Inc. from 2012 to 2014, as a director of Delphi Digital, Inc. since March 2012, as a director and as Chairman of the Board of Zyversa Therapeutics, a biotechnology company, since October 2016 and August 2018, respectively, and as Chairman of the Scientific Board of Advisors for Noble Capital Financial Markets since February 2012.